Global Autism Disorder and Treatment Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022 .
Autism Disorder and Treatment Market - Overview Autism spectrum disorder (ASD) is a group of complex neurological disorders characterized by varied patterns of behaviour, and problems with social communication and interaction. The major signs, and symptoms of ASD includes compulsive behaviour, inappropriate social interaction, learning disability, anxiety, sensitivity to sound, repetitive movements, and many others. As per the 2017 reviewed data suggested by Centers for disease control and prevention, it is observed that nearly 1 in 68 children has been diagnosed with autism spectrum disorder (ASD). It is also reported that the condition is 4.5 times more common among boys than among girls. On considering the economic costs, it is observed that around USD 11.5 billion – 60.9 billion have been invested per year for patients dealing with ASD n the United States. In addition to medical costs, other behavioral interventions for children with ASD costs around USD 40,000 - 60,000 per child per year. For instance, on June 1, 2017, the U.S. based Autism Society conducted 49th annual conference focuses on quality of life. Rising research & development activities have also attracted a great deal of attention. The Autism CARES Act extended federal coverage of autism research activities by five years with $1.3 billion funding. Despite these significant driving factors, there are some issues associated with market. Patent expiration of drugs is expected to decline the market growth in near future.
Ask For Sample Report: https://www.marketresearchfuture.com/sample_request/1605 .
Market Players Try to Find Their Winning Formulas to reach unmet needs The Autism Disorder and Treatment market is currently dominated by various few players. BristolMyers Squibb and Otsuka Holdings Co., Ltd. are one of those by holding a strong share in the market. Bristol-Myers Squibb is a U.S. based pharmaceutical company and Otsuka Holdings Co., Ltd. has head office in Japan. Both the companies in collaboration introduced ABILIFYÂŽ (aripiprazole) drug for the treatment of conditions associated with autistic disorder. The drug had received approval November 20, 2009. Currently, there are only two FDA approved drugs for autistic disorder in the market i.e., Abilify (aripiprazole) and risperidone. Risperidone is a secondgeneration antipsychotic drug, received approval from FDA to treat autistic disorders in 2006.
Regional Analysis: Autism Disorder and Treatment Market The Autism Disorder and Treatment Market is expected to be concentrated across the eight major countries such as US, Canada, France, UK, Germany, Spain, Italy, and, Japan. Regional market analysis reflects the dominance of developed world on the Autism disorder treatment market. North America leads the world and is closely followed by Europe. The Asian continent is led by Japan. A close observation will reflect the fact that increasing screening is the likely cause of